We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
Moderna (MRNA - Free Report) closed at $40.60 in the latest trading session, marking a +2.52% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.53%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 1%.
Coming into today, shares of the biotechnology company had gained 32.49% in the past month. In that same time, the Medical sector gained 0.09%, while the S&P 500 gained 2.06%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. The company is forecasted to report an EPS of -$2.79, showcasing a 11.6% downward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $683.27 million, down 29.27% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$7.98 per share and revenue of $0 million, indicating changes of +10.03% and 0%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Moderna. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.14% higher. Moderna is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 96, this industry ranks in the top 40% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
Moderna (MRNA - Free Report) closed at $40.60 in the latest trading session, marking a +2.52% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.53%. Meanwhile, the Dow lost 0.09%, and the Nasdaq, a tech-heavy index, lost 1%.
Coming into today, shares of the biotechnology company had gained 32.49% in the past month. In that same time, the Medical sector gained 0.09%, while the S&P 500 gained 2.06%.
The investment community will be paying close attention to the earnings performance of Moderna in its upcoming release. The company is forecasted to report an EPS of -$2.79, showcasing a 11.6% downward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $683.27 million, down 29.27% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$7.98 per share and revenue of $0 million, indicating changes of +10.03% and 0%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Moderna. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.14% higher. Moderna is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 96, this industry ranks in the top 40% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.